Vertex Pharmaceuticals
VRTX
1,670 hedge funds and large institutions have $110B invested in Vertex Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 274 funds opening new positions, 620 increasing their positions, 566 reducing their positions, and 99 closing their positions.
177% more first-time investments, than exits
New positions opened: 274 | Existing positions closed: 99
114% more funds holding in top 10
Funds holding in top 10: 7 → 15 (+8)
35% more call options, than puts
Call options by funds: $877M | Put options by funds: $649M
21% more capital invested
Capital invested by funds: $90.8B → $110B (+$18.7B)
10% more funds holding
Funds holding: 1,521 → 1,670 (+149)
4.67% more ownership
Funds ownership: 90.59% → 95.26% (+4.7%)
10% more repeat investments, than reductions
Existing positions increased: 620 | Existing positions reduced: 566
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$2.48B |
| 2 |
BlackRock
New York
|
+$646M |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
+$478M |
| 4 |
Winslow Capital Management
Minneapolis,
Minnesota
|
+$383M |
| 5 |
Capital Research Global Investors
Los Angeles,
California
|
+$329M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Parnassus Investments
San Francisco,
California
|
-$646M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$470M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$410M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$330M |
| 5 |
DZ Bank
Frankfurt Am Main,
Germany
|
-$232M |
VRTX Hedge Fund Activity: Q4 2025 in Review
1,670 institutional investors reported a position in Vertex Pharmaceuticals (VRTX) for Q4 2025, worth a combined $110B — up 21% from $90.8B a quarter earlier.
Buyers outnumbered sellers: 274 funds opened new VRTX positions and 99 closed out — a net gain of 175 holders — while 620 added to existing stakes and 566 trimmed.
The largest buyer was Invesco, adding an estimated $2.48B. The largest seller was Parnassus Investments, exiting entirely with an estimated $646M sold.
- 1,670 institutional investors held Vertex Pharmaceuticals (VRTX) as of Q4 2025, up from 1,521 in Q3 2025.
- Funds reported $110B of Vertex Pharmaceuticals stock for Q4 2025, up 21% quarter-over-quarter.
- 274 funds opened new Vertex Pharmaceuticals positions in Q4 2025 and 99 closed out, a net change of +175 holders.
- The largest Vertex Pharmaceuticals buyer in Q4 2025 was Invesco, an estimated $2.48B added.
- The largest Vertex Pharmaceuticals seller in Q4 2025 was Parnassus Investments, an estimated $646M sold.
Based on aggregated 13F filings for Q4 2025.